3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
19
Kidney Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
von Hippel-Lindau Disease
4
Neoplasm Metastasis
2
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Glioblastoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
3-Iodobenzylguanidine
5
spartalizumab
1
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
belzutifan
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Melphalan
1
Lutetium-177
1
Lutetium
1
Iodine-131
1
Immunotherapy
1
Everolimus
1
Drug Therapy
1
Biological Therapy
1
3-fluorobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pheochromocytoma
×
belzutifan
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA